Literature DB >> 8932340

Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas.

J Papp1, B Csokay, P Bosze, Z Zalay, J Toth, B Ponder, E Olah.   

Abstract

Using a panel of ten polymorphic markers, we examined the frequency of loss of heterozygosity (LOH) on chromosome 17 in 55 sporadic ovarian tumours. LOH on 17p and 17q was observed to be 50% and 62% respectively. LOH at D17S5 was detected in 24/36 (67%) of malignant cases and in 19/43 (44%) at TP53; the marker D17S855 intragenic to the BRCA1 gene showed allele loss in 50% (20/40) cases. The data presented here suggest that loss of the whole chromosome 17 is a relatively frequent event (30%) in ovarian carcinomas and this observation is especially frequent for serous, transitional cell and anaplastic histological subtypes. Mucinous and endometrioid ovarian tumours showed only short interstitial deletions (4/11, 36%). The overall frequency of the short deletions was relatively low (7/43, 16%) in our panel of carcinomas. Amplification of c-erbB-2/neu oncogene was detected in 32% (11/34) of the carcinomas tested; the gene was amplified only in those histological subtypes in which high incidence of LOH on chromosome 17 was observed, and was associated with advanced stages of the disease. We conclude that different histological types of tumour may have different aetiological mechanisms, and tumour-suppressor genes on chromosome 17 might be associated specifically with serous and transitional cell ovarian carcinomas.

Entities:  

Mesh:

Year:  1996        PMID: 8932340      PMCID: PMC2074870          DOI: 10.1038/bjc.1996.594

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Telomere reduction in human colorectal carcinoma and with ageing.

Authors:  N D Hastie; M Dempster; M G Dunlop; A M Thompson; D K Green; R C Allshire
Journal:  Nature       Date:  1990-08-30       Impact factor: 49.962

2.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

3.  Allele loss from chromosome 17 in ovarian cancer.

Authors:  S E Russell; G I Hickey; W S Lowry; P White; R J Atkinson
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

4.  Allele losses on chromosome 17 in human epithelial ovarian carcinoma.

Authors:  D M Eccles; G Cranston; C M Steel; Y Nakamura; R C Leonard
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

5.  p53 mutation is a common genetic event in ovarian carcinoma.

Authors:  B J Milner; L A Allan; D M Eccles; H C Kitchener; R C Leonard; K F Kelly; D E Parkin; N E Haites
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

6.  Allelic loss in ovarian cancer.

Authors:  T L Yang-Feng; H Han; K C Chen; S B Li; E B Claus; M L Carcangiu; S K Chambers; J T Chambers; P E Schwartz
Journal:  Int J Cancer       Date:  1993-06-19       Impact factor: 7.396

7.  Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.

Authors:  W D Foulkes; D M Black; G W Stamp; E Solomon; J Trowsdale
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

8.  Growth retardation and tumour inhibition by BRCA1.

Authors:  J T Holt; M E Thompson; C Szabo; C Robinson-Benion; C L Arteaga; M C King; R A Jensen
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

9.  Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas.

Authors:  J H Lee; J J Kavanagh; D M Wildrick; J T Wharton; M Blick
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

10.  Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis.

Authors:  C Coles; A M Thompson; P A Elder; B B Cohen; I M Mackenzie; G Cranston; U Chetty; J Mackay; M Macdonald; Y Nakamura
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

View more
  6 in total

1.  STRAD in Peutz-Jeghers syndrome and sporadic cancers.

Authors:  W W J de Leng; J J Keller; S Luiten; A R Musler; M Jansen; A F Baas; F W M de Rooij; J J P Gille; F H Menko; G J A Offerhaus; M A J Weterman
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

2.  Allelic Losses from Chromosome 17 in Human Osteosarcomas.

Authors:  Marianna Sztán; Zsuzsa Pápai; Miklós Szendrôi; Marco van der Looij; Edith Oláh
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

3.  Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.

Authors:  Karen M Chisholm; Barbara A Goff; Rochelle Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Cancer Genet Cytogenet       Date:  2008-05

4.  The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Authors:  Paulina M Wojnarowicz; Kathleen Klein Oros; Michael C J Quinn; Suzanna L Arcand; Karen Gambaro; Jason Madore; Ashley H Birch; Manon de Ladurantaye; Kurosh Rahimi; Diane M Provencher; Anne-Marie Mes-Masson; Celia M T Greenwood; Patricia N Tonin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

5.  Network and data integration for biomarker signature discovery via network smoothed T-statistics.

Authors:  Yupeng Cun; Holger Fröhlich
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

Review 6.  Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.

Authors:  Jerry Vriend; Mark W Nachtigal
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.